JP2013515049A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515049A5
JP2013515049A5 JP2012545493A JP2012545493A JP2013515049A5 JP 2013515049 A5 JP2013515049 A5 JP 2013515049A5 JP 2012545493 A JP2012545493 A JP 2012545493A JP 2012545493 A JP2012545493 A JP 2012545493A JP 2013515049 A5 JP2013515049 A5 JP 2013515049A5
Authority
JP
Japan
Prior art keywords
composition
klh
concentration
present
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012545493A
Other languages
English (en)
Japanese (ja)
Other versions
JP6007105B2 (ja
JP2013515049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/055674 external-priority patent/WO2011077309A2/en
Publication of JP2013515049A publication Critical patent/JP2013515049A/ja
Publication of JP2013515049A5 publication Critical patent/JP2013515049A5/ja
Application granted granted Critical
Publication of JP6007105B2 publication Critical patent/JP6007105B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012545493A 2009-12-22 2010-12-08 ワクチン組成物 Expired - Fee Related JP6007105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
US61/289,083 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015105966A Division JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Publications (3)

Publication Number Publication Date
JP2013515049A JP2013515049A (ja) 2013-05-02
JP2013515049A5 true JP2013515049A5 (enExample) 2014-01-30
JP6007105B2 JP6007105B2 (ja) 2016-10-12

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012545493A Expired - Fee Related JP6007105B2 (ja) 2009-12-22 2010-12-08 ワクチン組成物
JP2015105966A Expired - Fee Related JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015105966A Expired - Fee Related JP6146927B2 (ja) 2009-12-22 2015-05-26 ワクチン組成物

Country Status (13)

Country Link
US (3) US20130034573A1 (enExample)
EP (2) EP3257525A3 (enExample)
JP (2) JP6007105B2 (enExample)
KR (1) KR20120120185A (enExample)
CN (2) CN102762224A (enExample)
AU (1) AU2010334428B2 (enExample)
CA (1) CA2785585A1 (enExample)
IL (1) IL220308A0 (enExample)
MX (1) MX337070B (enExample)
NZ (2) NZ600978A (enExample)
RU (1) RU2581020C2 (enExample)
SG (2) SG10201408505SA (enExample)
WO (1) WO2011077309A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012020855B8 (pt) * 2010-02-21 2021-05-25 Bayer Healthcare Llc método para produzir um conjugado de biomolécula
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20210027493A (ko) 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (enExample) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69532767T2 (de) * 1994-11-28 2004-08-12 Thomas Jefferson University Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ATE258310T1 (de) * 1997-07-31 2004-02-15 Metra Biosystems Inc Testverfahren für collagenpeptid
ATE505478T1 (de) * 1997-08-27 2011-04-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkalen b epitopen
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥c反応性タンパク質組成物
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2003068259A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
JP4393382B2 (ja) * 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
KR101531400B1 (ko) * 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
PL1684719T3 (pl) * 2003-11-14 2012-11-30 Baxalta Inc Kompozycje alfa 1-antytrypsyny i sposoby leczenia z zastosowaniem takich kompozycji
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ, リミテッド 先天免疫応答を誘導するための方法および組成物
KR20100018029A (ko) 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
CN101222941A (zh) * 2005-05-24 2008-07-16 尼奥瓦克斯公司 用于制备包含TNFα和载体蛋白质的抗原杂络物的稳定的免疫原产品的方法
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
NZ586383A (en) * 2007-12-28 2012-11-30 Baxter Int Recombinant vwf formulations

Similar Documents

Publication Publication Date Title
JP2013531679A5 (enExample)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
JP2016534052A5 (enExample)
RU2011127913A (ru) Составы, содержащие антитела
KR20200097295A (ko) 분지형 링커를 갖는 튜불리신 유사체의 접합체
KR20210125094A (ko) 비스-링키지를 사용한 세포독성 약물의 접합
JP2013515049A5 (enExample)
JP2021504372A5 (enExample)
WO2016154621A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
IL294463A (en) Methods for treating or preventing eye conditions
JP2013511557A5 (enExample)
RU2013128361A (ru) Her2-связывающие белки, меченые комплексом 18f-фторида алюминия и nota
JP2012521201A5 (enExample)
JP2017514868A5 (enExample)
JP2007534698A5 (enExample)
JP2016520075A5 (enExample)
JP7126270B2 (ja) Npraアゴニスト、組成物およびその使用
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
US20200254054A1 (en) Daptomycin formulations
JP6580581B2 (ja) 注射用医薬組成物
CN110494164A (zh) 一种靶向治疗TNF-α相关疾病的人抗体制剂
RU2018129077A (ru) Стабильная фармацевтическая композиция
RU2012131162A (ru) Композиции вакцин
SI2968442T1 (en) New stable pentadecapeptide salts, a process for their preparation, their use in the manufacture of pharmaceutical preparations and their use in therapy
KR20220034053A (ko) 재조합 단백질의 안정적인 제형